New Zealand markets closed

Altimmune, Inc. (3G0.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
6.38+0.10 (+1.66%)
At close: 08:14AM CEST
Full screen
Previous close6.27
Open6.38
Bid6.78 x 440000
Ask6.82 x 420000
Day's range6.38 - 6.38
52-week range1.97 - 13.70
Volume50
Avg. volume346
Market cap491.613M
Beta (5Y monthly)0.20
PE ratio (TTM)N/A
EPS (TTM)-1.48
Earnings date08 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date20 Jan 2017
1y target est30.86
  • GlobeNewswire

    Altimmune to Participate at Two Upcoming Investor Conferences

    GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20

  • GlobeNewswire

    Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024

    GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data on the anti-inflammatory and anti-fibrotic properties of pemvidutide in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) will be presented at the EASL International Liver Congress™ 2024 in Milan, Italy. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for

  • PR Newswire

    Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

    Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today. OZEM is the world's first ETF focused exclusively on the rapidly growing sector of GLP-1 receptor agonists and other weight management drugs.